Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mifepristone - Corcept Therapeutics

Next Previous
X
Search
Drug Profile

Mifepristone - Corcept Therapeutics

Alternative Names: C 1073; Corlux; Corluxin; Korlym; Mifegyne; Mifeprex; RU 38486; RU-486

Latest Information Update: 04 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roussel Uclaf; Stanford University
  • Developer Corcept Therapeutics; Danco Laboratories; Population Council (USA); pSivida; Stanford University; University of Chicago
  • Class Abortifacients; Antidementias; Antidepressants; Antiglaucomas; Antineoplastics; Antiprogestogens; Antipsychotics; Antivirals; Dimethylamines; Estrenes; Eye disorder therapies; Obesity therapies; Oral contraceptives; Small molecules; Smoking cessation therapies
  • Mechanism of Action Glucocorticoid receptor antagonists; Progesterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cushing syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cushing syndrome; Induced abortion
  • Phase II Alcoholism; Breast cancer; Major depressive disorder
  • Phase I/II Prostate cancer
  • No development reported Central serous chorioretinopathy; Non-small cell lung cancer; Smoking withdrawal
  • Discontinued Alzheimer's disease; Obesity; Ocular hypertension; Psychotic affective disorders

Most Recent Events

  • 04 Jan 2024 The U.S. Court for the District of New Jersey rules that Teva Pharmaceuticals does not infringe any asserted claims of Corcept Therapeutics patent no. 10 195 214 and 10 842 800 in the USA
  • 02 Jun 2023 Interim adverse events and efficacy data from a phase-II trial in Breast cancer presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 17 Apr 2023 US Supreme Court issued an administrative stay on Mifepristone in treatment of pregnancy termination in US

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top